Investigational drug · Phase 2
GL0034
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Type II Diabetes Mellitus.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "GL0034"
First trial start
2026
Jan 20, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GL0034", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type II Diabetes Mellitus
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "GL0034" as an intervention, largest first.
- Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes MellitusPivotal-lookingRecruiting
Sun Pharmaceutical Industries LimitedIndustry
NCT07282743 · 285 participants (planned) · Start Jan 20, 2026 · Primary completion Apr 2027
Drug: GL0034 Dose Level 1; GL0034 Dose Level 2 and 4 more · For: Type II Diabetes Mellitus
Sites: Little Rock, Arkansas; Hialeah Gardens, Florida; Lakeland, Florida · 21 sites in all
- Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal InsufficiencyRecruiting
Sun Pharmaceutical Industries LimitedIndustry
NCT07385547 · 40 participants (planned) · Start Feb 25, 2026 · Primary completion Sep 2026
Drug: GL0034 · For: Type II Diabetes Mellitus
Sites: Miami, Florida; Miami Lakes, Florida; Orlando, Florida
Newest research
PubMed records naming it or its code names, newest first.
- In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist.
Jones B, Burade V, Akalestou E, et al. · Diabetes Obes Metab 2022
Also in development for Type II Diabetes Mellitus
- VCT220CX11Phase 35 trials
Vincentage Pharma Co., Ltd · Obesity, Type 2 Diabetes Mellitus (DM), Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.